GALECTO
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
GALECTO
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2011-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.galecto.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
160.41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome IPv6 ReCAPTCHA
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
CG Oncology
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Janus Henderson Investors
Janus Henderson Investors investment in Series D - Galecto
Hadean Ventures
Hadean Ventures investment in Series D - Galecto
Bristol Myers Squibb
Bristol Myers Squibb investment in Series D - Galecto
Canica
Canica investment in Series D - Galecto
Seventure Partners
Seventure Partners investment in Series D - Galecto
OrbiMed
OrbiMed investment in Series D - Galecto
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - Galecto
EIR Ventures
EIR Ventures investment in Series D - Galecto
Ysios Capital
Ysios Capital investment in Series D - Galecto
Sphera Funds Management
Sphera Funds Management investment in Series D - Galecto
Official Site Inspections
http://www.galecto.com Semrush global rank: 3.49 M Semrush visits lastest month: 4.29 K
- Host name: 567964.cloudwaysapps.com
- IP address: 167.71.79.29
- Location: Amsterdam Netherlands
- Latitude: 52.352
- Longitude: 4.9392
- Timezone: Europe/Amsterdam
- Postal: 1098
